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Background: Chloride intracellular channel 1 (CLIC1) is expressed ubiquitously in human tissues and is involved in
the regulation of cell cycle, cell proliferation and differentiation. Recent studies have shown that CLIC1 is highly
expressed in several human malignant tumors. However, its roles in human gliomas are still unclear. The aim of this
study was to investigate the clinicopathological significance and prognostic value of CLIC1 expression in human
gliomas.
Methods: CLIC1 expression in human gliomas and nonneoplastic brain tissues was measured by real-time
quantitative RT-PCR assay and immunohistochemistry. Its association with clinicopathological factors or prognosis in
patients with gliomas was statistically analyzed.
Results: The expression of CLIC1 at both mRNA and protein levels was significantly increased in high-grade (Grade
III~IV) glioma tissues compared with that in low-grade (Grade I~II) and nonneoplastic brain tissues, and was
up-regulated with ascending tumor World Health Organization (WHO) grades. The elevated expression of CLIC1
protein was also significantly correlated with low Karnofsky performance score (KPS) (P=0.008). Moreover, both
univariate and multivariate analysis shown that high CLIC1 expression was significantly associated with poor
prognosis in patients with gliomas (P<0.001 and P=0.01, respectively). In particular, the elevated CLIC1 expression
also correlated with shorter overall survival in different glioma subgroups stratified according to the WHO grading.
Conclusions: Our data provide the first evidence that CLIC1 expression might play an important role in the
regulation of aggressiveness in human gliomas. The elevated expression of CLIC1 might represent a valuable
prognostic marker for this disease.
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PrognosisIntroduction
Human gliomas represent the most common primary brain
tumors in both children and adults. According to histo-
pathological and clinical criteria established by the World
Health Organization (WHO), this dismal disease can be
classified as well-differentiated low grade astrocytomas* Correspondence: zhangys_td@163.com; gguodong1@163.com
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reproduction in any medium, provided the or[World Health Organization (WHO) grade I~II], anaplastic
astrocytomas (WHO grade III) and glioblastoma multi-
forme (GBM, WHO grade IV) [1]. Despite recent thera-
peutic advances, the survival of patient with glioma is still
poor. The median overall survival of patients with malig-
nant gliomas is no more than one year and local recurrence
occurs in more than 90% of patients [2]. Recent studies
have indicated that patients’ age, Karnofsky performance
status (KPS) score, histologic grade, and tumor necrosis are
important prognostic factors for gliomas [3]. However, the
prognosis of both high- and low-grade tumors remains het-
erogeneous. The median survival time of patients withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with low-grade tumors also present poor outcome
[4]. Similar with other human solid tumors, the predomin-
ant features of gliomas are extensive local tumor invasion
and metastasis, in which multiple molecular events are
involved. Focusing on these genetic background and mo-
lecular pathogenic processes is necessary to identify novel
diagnostic and prognostic markers for improving the clin-
ical outcome of patients with gliomas.
In mammals, the chloride intracellular channel (CLIC)
gene family has six members, including CLIC1, CLIC2,
CLIC3, CLIC4, CLIC5, and CLIC6 [5]. This family is
defined by a conserved, approximately 230 amino acid
core sequence which comprises the C-termini of all
known CLICs. CLIC1 is a newly discovered member of
the CLIC family [6]. In 1997, it was originally cloned from
a human monocytic cell line activated by the phorbol
ester, phorbol 12-myristate 13 acetate [7]. CLIC1 is
expressed ubiquitously in human tissues and is usually
localized in the cytoplasm and nucleoplasm with a soluble
form. It has been demonstrated to be involved in the regu-
lation of cell cycle, cell proliferation and differentiation
[8]. In the G2/M phase, CLIC1 is detected on the plasma
membranes of cells, and the inhibition of CLIC1 function
prolongs the mean time of the cell cycle in cell culture [9].
Recent studies have found that CLIC1 is over-expressed in
malignant tumors, such as hepatocellular carcinoma [10],
gallbladder carcinoma [11], gastric carcinoma [12], and
colorectal cancer [13,14]. CLIC1 has been considered as a
sensor and an effector during oxidative stress, which may
lead cells through all the phases of the cell cycle [15].
Thus, CLIC1 is hyperactivated in cancer cells which are inTable 1 Clinicopathological features of 128 patients with glio
Features WHO I
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Radiotherapy and Chemotherapy combination 0a highly proliferative state, and plays important roles in
tumor invasion and metastasis.
In central nervous system, several lines of evidence
support that CLIC1 plays a fundamental role in activated
microglia and is involved in the pathophysiology of sev-
eral neurodegenerative diseases [16]. Additionally, Kang
et al. [17] found that small cell populations of GBM2
cancer stem cells (CSCs) were resistant to chemothera-
peutic agent BCNU and highly expressed CLIC1. They
further demonstrated that CLIC1 was involved in the re-
sistance of BCNU-resistant CSCs. However, the clinico-
pathological significance and prognostic value of CLIC1
in clinical glioma specimens are still unclear. To address
this problem, CLIC1 expression in human gliomas and
nonneoplastic brain tissues were measured by immuno-
histochemistry. The association of CLIC1 immunostain-
ing with clinicopathological factors or prognosis of
glioma patients was statistically analyzed.
Materials and methods
Patients and tissue samples
This study was approved by the Research Ethics Com-
mittee of Tangdu Hospital, Fourth Military Medical Uni-
versity, P. R. China. Written informed consent was
obtained from all of the patients. All specimens were
handled and made anonymous according to the ethical
and legal standards.
A total of 128 formalin-fixed, paraffin-embedded spe-
cimens of gliomas resected between 2000 and 2010 were
retrieved from the archives of the Pathology Department
of Tangdu Hospital, Fourth Military Medical University,
P. R. China. All the slides were re-evaluated according tomas
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ences resolved by careful discussion. A total of 76 males
and 52 females (1.46:1) were enrolled in this study, and
the median age was 42 years (range, 12–71). Thirty-two
of the 128 gliomas were classified as low-grade [18 pilo-
cytic astrocytomas (WHO I) and 14 diffuse astrocytomas
(WHO II)], and 96 were classified as high-grade gliomas
[38 anaplasia astrocytomas (WHO III), and 58 primary
glioblastomas (WHO IV)]. None of the patients had
received chemotherapy or radiotherapy prior to surgery.
The clinicopathological features and the treatment strat-
egies of all the patients were indicated in Table 1. Paraf-
fin and snap-frozen sections of nonneoplastic brain
tissues from 10 patients with intractable epilepsy were
also included as controls.
In addition, 20 glioma specimens [5 pilocytic astrocy-
tomas (WHO I), 3 diffuse astrocytomas (WHO II), 3
anaplasia astrocytomas (WHO III), and 9 primary glio-
blastomas (WHO IV)] were snap-frozen in liquid nitro-
gen and stored at −80°C following surgery for real-time
quantitative RT-PCR assay.
Five years follow-up was performed, and all patients
had complete follow-up until death. Overall survival
time was calculated from the date of the initial surgical
operation to death. Patients, who died of diseases not
directly related to their gliomas or due to unexpected
events, were excluded from this study.
Immunohistochemistry assay
Formalin-fixed, paraffin-embedded, sectioned tissues (4
μm thick) were immunostained using the Labelled Strep-
tavidin Biotin 2 System (BioGenex; San Ramon, CA,
USA). Following peroxidase blocking with 0.3% H2O2/
methanol for 30 min, specimens were blocked with
phosphate-buffered saline (PBS) containing 5% normal
horse serum (Vector Laboratories Inc., Burlingame, CA,
USA). All incubations with mouse anti-human CLIC1
monoclonal antibody (1:175 dilution, Abcam,Cambridge,
UK) were carried out overnight at 4°C. The specificity of
this primary antibody has been demonstrated in previous
studies of Wang et al. [11]. Then the specimens were
briefly washed in PBS and incubated at room temperature
with the anti-mouse antibody and avidin-biotin peroxidase
(Vector Laboratories Inc., Burlingame, CA, USA). The
specimens were then washed in PBS and color-developed
by diaminobenzidine solution (Dako Corporation, Carpin-
teria, CA, USA). After washing with water, specimens
were counterstained with Meyer’s hematoxylin (Sigma
Chemical Co., St Louis, MO, USA). Nonneoplastic brain
tissues were used as control tissues and non-immune IgG
was also used as negative control antibody for immunohis-
tochemical staining.
Assessment of immunohistochemical staining was eval-
uated by two independent pathologists. The scores of thetwo pathologists were compared and any discrepant
scores were trained through re-examining the stainings by
both pathologists to achieve a consensus score. The num-
ber of positive-staining cells showing immunoreactivity in
cytoplasm for CLIC1 in ten representative microscopic
fields was counted and the percentage of positive cells was
calculated. The percentage scoring of immunoreactive
tumor cells was as follows: 0 (0%), 1 (1–10%), 2 (11–50%)
and 3 (>50%). The staining intensity was visually scored
and stratified as follows: 0 (negative), 1 (weak), 2 (moder-
ate) and 3 (strong). A final immunoreactivity scores (IRS)
was obtained for each case by multiplying the percentage
and the intensity score. Protein expression levels were fur-
ther analyzed by classifying IRS values as low (based on a
IRS value less than 5) and as high (based on a IRS value
greater than 5).
Real-time quantitative RT-PCR
The mRNA expression of CLIC1 in glioma and non-
neoplastic brain tissues was detected by real-time quan-
titative RT-PCR analysis according to the conventional
protocols of Tangdu hospital [18]. Especially, the primers
were designed as follows: for human CLIC1, forward pri-
mer, 5′- ATG GCT GAA GAA CAA CCG -3′, and re-
verse primer, 5′- TTA TTT GAG GGA CTT TGA -3′;
for human glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), forward primer, 5′- CCC ACT CCT CCA
CCT TTG AC-3′, and reverse primer, 5′-ATG AGG
TCC ACC ACC CTG TT-3′. Each sample was examined
in triplicate and the amounts of the PCR products pro-
duced were non-neoplasticized to GAPDH which served
as internal control.
Statistical analysis
All computations were carried out using the software of
SPSS version13.0 for Windows (SPSS Inc, IL, USA). Data
were expressed as means±standard deviation (SD). The
analysis of variance (ANOVA) was used to determine
the statistical differences among the groups. A life table
was calculated according to the Kaplan-Meier method.
Hazard ratios for the time-to-event endpoint were esti-
mated using the multivariate Cox regression analysis in a
forward stepwise method to evaluate the effect of mul-
tiple independent prognostic factors on survival out-
come. Differences were considered statistically significant
when p was less than 0.05.
Results
CLIC1 mRNA expression in human glioma tissues
The expression levels of CLIC1 mRNA were detected in
20 glioma and 10 non-neoplastic brain tissues normalized
to GAPDH. As shown in Figure 1A, the expression levels
of CLIC1 mRNA were found to be distinctly increased in
glioma tissues compared to non-neoplastic brain tissues,
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results (Figure 1B) showed that its expression in high-
grade (III-IV; 2.2±0.08) and low-grade (I-II; 1.6±0.06)
gliomas were both significantly higher than that in non-
neoplastic brains tissues (0.3±0.01; both P<0.001). Add-
itionally, there was also a significant difference in mRNA
copies of CLIC1 between high-grade (III-IV) and low
-grade (I-II) glioma tissue specimens (P=0.002).Elevated expression of CLIC1 protein in human glioma
tissues
The expression of CLIC1 protein was detected in 128
glioma specimens and 10 nonneoplastic brain tissues
using immunohistochemical staining. Representative
photographs of CLIC1 immunostainings were shown in
Figure 2. In the glioma sections, CLIC1 was mainly
detected in the cytoplasm (Figure 2A), which was con-
sistent with previous studies on other cancers [10-12]. In
contrast, the non-neoplastic brain tissues expressed a
trace amount of CLIC1 (Figure 2B). CLIC1 was not
present in negative controls with non-immune IgG
(Figure 2C) and in normal gastric tissues (Figure 2D).
Of the 128 patients with gliomas, the high expression
of CLIC1 was detected in 69.5% (89/128) of patients. For
WHO grade III and IV tumors, 79.2% (76/96) of cases
highly expressed CLIC1. However, for grade I and gradeFigure 1 CLIC1 mRNA expression in 20 glioma tissues with
different grades and in non-neoplastic brain tissues were
detected by real-time quantitative RT-PCR assay. (A) Expression
levels of CLIC1 mRNA in glioma tissues with different grades and
non-neoplastic brain tissues. (B) A graphical representation of the
CLIC1 mRNA level expression profiles in (A). ‘N’ refers to non-
neoplastic brain tissues; ‘I~II’ refers to glioma tissues with grade I~II;
‘III~IV’ refers to glioma tissues with grade III~IV.II tumors, 40.6% (13/32) of cases highly expressed
CLIC1. According to these results, increased expression
of CLIC1 was found to be associated with the histo-
pathologic grading of the gliomas.Association of CLIC1 expression with clinicopatholigcal
features of gliomas
The associations of CLIC1 protein expression with the
clinicopathological factors of the glioma patients were
summarized in Table 2. The over-expression of CLIC1
was detected in high-grade glioma tissues compared
with those in low-grade tissues, and increased with
ascending tumor WHO grades (P=0.005, Table 2). The
increased expression of CLIC1 protein was also signifi-
cantly correlated with low Karnofsky performance score
(KPS) (P=0.008, Table 2). No statistically significant asso-
ciations of CLIC1 with age at diagnosis and gender of
patients were found (both P>0.05, Table 2).Association of CLIC1 expression with overall survival in
patients with gliomas
Kaplan-Meier analysis using the log-rank test was per-
formed to determine the association of CLIC1 expression
with clinical outcome of glioma patients (Figure 3A). The
results shown that high expression of CLIC1 was mark-
edly associated with a shorter overall survival (P<0.001).
During the follow-up period, 100 of 128 glioma patients
(78.1%) had died. Of patients with high CLIC1 expression,
81 (81/89, 91.0%) were died; in contrast, 19 (19/39, 48.7%)
of patients with low CLIC1 expression were died. The me-
dian survival time of patients with high CLIC1 expression
(28.6 months, 95% confidence interval: 25.6–33.9) was sig-
nificantly shorter than that of patients who had low CLIC1
expression level (50.1 months, 95% confidence interval:
41.2–58.6, P<0.001).
Nextly, the univariate analysis of individual variables
revealed strong relationships between overall survival and
WHO grade (P< 0.001), and CLIC1 expression (P<0.001).
Additionally, the multivariate analysis identified CLIC1 ex-
pression (HR, 4.66; 95% CI, 2.31–10.29; P=0.01) and
WHO grade (HR, 6.97; 95% CI, 2.12–12.46; P=0.008) as
significant prognostic factors for glioma (Table 3).
Furthermore, we evaluated the prognostic significance
of CLIC1 protein expression levels in different sub-
groups of glioma patients stratified according to the
WHO grading. Notably, high CLIC1 expression also sig-
nificantly correlated with shorter overall survival time in
different glioma subgroups. Overall survival of glioma
patients with high CLIC1 expression was significantly
decreased than those with low CLIC1 expression in ei-
ther Grades I~II subgroup (n=32; P=0.01; Figure 3B) or
Grades III~IV subgroup (n=96; P=0.008; Figure 3C).
Figure 2 Representative photographs for CLIC1 immunostaings in glioma tissues with WHO grade IV (A, Original magnification×400)
and nonneoplastic brain tissues (B, Original magnification×400). In glioma tissues, the immunostaining of CLIC1 was mainly expressed in the
cytoplasm of tumor cells with brown yellow (marked by arrows). In contrast, Negative immunostaining was shown in the non-neoplastic brain
tissues. Additionally, CLIC1 was not present in negative controls with non-immune IgG (Figure 1C, Original magnification×400) and in normal
gastric tissues (Figure 1D, Original magnification×200).
Table 2 Association of CLIC1 protein expression in human







High (n, %) Low (n, %)
Age
<55 52 36 (69.2) 16 (30.8) NS
≥55 76 53 (69.7) 23 (30.3)
Gender
Male 76 51 (67.1) 25 (32.9) NS
Female 52 38 (73.1) 14 (26.9)
WHO grade
I 18 6 (33.3) 12 (66.7) 0.005
II 14 7 (50.0) 7 (50.0)
III 38 26 (68.4) 12 (31.6)
IV 58 50 (86.2) 8 (13.8)
KPS
<80 78 61 (78.2) 17 (21.8) 0.008
≥80 50 28 (56.0) 22 (44.0)
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Similar with other human solid tumor cells, the glioma
cells do not only have limitless replicative potential
but also readily invade surrounding brain tissues and
metastasize to other tissues, which make complete sur-
gical resection practically impossible and lead to poor
prognosis. Therefore, molecules involved in the aggres-
sive process are potential prognostic and therapeutic
markers. In the present study, our data shown for the
first time that the up-regulation of CLIC1 at both
mRNA and protein levels in glioma tissues compared
with its expression in non-neoplastic brain tissues.
Additionally, highly CLIC1 protein expression was sig-
nificantly correlated with advanced WHO stage and
low KPS scores, suggesting that this protein might be
of clinical relevance in the aggressiveness of gliomas.
Together with these findings, we also demonstrated
that CLIC1 expression was a statistically significant
risk factor affecting overall survival of patients with
glioma and was an independent risk factor predicting
short overall survival.
Figure 3 Kaplan-Meier survival curves for glioma patients with high CLIC1 expression versus low CLIC1 expression. (A) The cumulative
5-year overall survival was significantly shorter for patients with high CLIC1 expression than those with low CLIC1 expression (P<0.001). (B and C)
Kaplan-Meier analysis showing the overall survival of glioma patients categorized according to the WHO grading criteria and status of CLIC1
expression. The cumulative 5-year overall survival was significantly different between high CLIC1 expression and low CLIC1 expression patients
within subgroups of WHO Grades I~II (B, P=0.01) and III~IV (C, P=0.008).
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a real chloride channel in plasma and nuclear mem-
branes [19]. The distribution of intracellular CLIC1 ex-
pression varies depending on the cell types, from
intracellular vesicular pattern to intranuclear distribu-
tion. Its physiological roles include ion homeostasis
modulation, cell volume regulation, transepithelial trans-
port, and regulation of electrical excitability [20]. Accu-
mulating number of studies have reported that CLIC1 is
up-regulated in many tumor cells, such as hepatocellular
carcinoma [10], gallbladder carcinoma [11], gastric can-
cer [12], colon cancer [13], nasopharyngeal carcinoma
[21], and breast cancer [22], and plays important roles in
tumor progression by modifying cell cycle, apoptosis,
cell adhesion, and promoting tumor metastasis. For ex-
ample, Chen et al. [12] found that the high levels of
CLIC1 expression in gastric cancer significantlyTable 3 Cox multivariate analysis
Parameter Risk ratio 95% confidence
interval
P
Age 0.89 0.58–1.65 0.71
Gender 1.02 0.66–1.83 0.33
WHO grade 6.97 2.12–12.46 0.008
KPS 1.99 1.28–2.95 0.06




CCL20 expression 4.66 2.31–10.29 0.01correlated with lymph node metastasis, lymphatic vessels
and surrounding tissues infiltration, pathological staging,
and survival time of patients; Wang et al. [23] shown
that CLIC1 expression in lung adenocarcinoma was
positively correlated with the T staging of the tumor and
was negatively correlated with the shorter postoperative
survival time of patients; Similarly, overexpression of
CLIC1 was detected in gallbladder carcinoma and also
found to significantly increase cell motility and invasion
of the poorly metastatic gallbladder carcinoma cell line
[11]. These results strongly imply that CLIC1 plays an
important role in tumor advancement. However, its con-
nection with human glioma has remained unknown.
Our current study provided the evidence in support of
such a connection using a cohort of 128 archived clinical
glioma specimens. We first detected high expression of
CLIC1 in glioma tissues compared with non-neoplastic
brain tissues. Further support for a possible role of
CLIC1 in glioma pathogenesis derived from the analysis
that revealed a strong correlation of CLIC1 expression
with the histopathological staging and inversely, with the
survival of the disease. These findings are consistent
with the previous reports which indicated that overex-
pression of CLIC1 is a potential prognostic marker for
hepatocellular carcinoma [9], gallbladder carcinoma [10],
gastric cancer [11], and lung adenocarcinoma [23].
In summary, our data provide the first evidence that
CLIC1 expression might play an important role in the regu-
lation of aggressiveness in human gliomas. The elevated ex-
pression of CLIC1 might represent a valuable prognostic
marker for this disease. This study adds to the current
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and progression of human malignant tumors.
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